"The trial was part of the ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines 6 (ACTIV-6), which was designed to assess the effectiveness of repurposed drugs such as ivermectin in the treatment of mild to moderate COVID-19.
Of all participants, 602 were randomly assigned to receive 600 micrograms per kilogram (μg/kg) of ivermectin once daily for 6 days, and 604 received a placebo. The dose used in previous RCTs showing futility of ivermectin for COVID-19 was 400 μg/kg once daily for 3 days, which some experts suggested was insufficient.
Both groups recovered in about 11 days
The median time to sustained recovery was 11 days in both the ivermectin and placebo groups (hazard ratio [HR], 1.02). Of the ivermectin recipients, 5.7% were hospitalized, died, or visited an urgent care center or emergency department, compared with 6.0% of placebo recipients (HR, 1.0).
One ivermectin recipient died, and 4 (0.8%) were hospitalized. Among placebo recipients, 2 (0.3%) were hospitalized, and none died. Adverse events were rare in both groups.
Despite the lack of efficacy in randomized, controlled trials, media reports and clinical experience suggests that some healthcare providers in the United States and abroad still prescribe ivermectin for their COVID-19 patients, according to an editor's note by Kirsten Bibbins-Domingo, PhD, MD, and Preeti Malani, MD, JAMA editor-in-chief and deputy editor, respectively."
https://www.cidrap.umn.edu/covid-19/higher-ivermectin-dose-longer-duration-still-futile-covid-trial-finds
(brought to you by GILEAD as supporter!)
"The trial was part of the ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines 6 (ACTIV-6), which was designed to assess the effectiveness of repurposed drugs such as ivermectin in the treatment of mild to moderate COVID-19.
Of all participants, 602 were randomly assigned to receive 600 micrograms per kilogram (μg/kg) of ivermectin once daily for 6 days, and 604 received a placebo. The dose used in previous RCTs showing futility of ivermectin for COVID-19 was 400 μg/kg once daily for 3 days, which some experts suggested was insufficient. Both groups recovered in about 11 days
The median time to sustained recovery was 11 days in both the ivermectin and placebo groups (hazard ratio [HR], 1.02). Of the ivermectin recipients, 5.7% were hospitalized, died, or visited an urgent care center or emergency department, compared with 6.0% of placebo recipients (HR, 1.0).
One ivermectin recipient died, and 4 (0.8%) were hospitalized. Among placebo recipients, 2 (0.3%) were hospitalized, and none died. Adverse events were rare in both groups.
Despite the lack of efficacy in randomized, controlled trials, media reports and clinical experience suggests that some healthcare providers in the United States and abroad still prescribe ivermectin for their COVID-19 patients, according to an editor's note by Kirsten Bibbins-Domingo, PhD, MD, and Preeti Malani, MD, JAMA editor-in-chief and deputy editor, respectively."